Lysosomal alterations, including increased expression of cathepsins, are common in cancer cells. 1 Targeting lysosomes has thus emerged as a new and promising possibility for the eradication of tumors. Lysosomes have a crucial role in programmed cell death pathways through the release of lysosomal hydrolases such as cathepsins B (CTSB) and L. 1, 2 Release of cathepsins is achieved through lysosomal membrane permeabilization (LMP). Thus, in response to endogenous or exogenous stress, LMP can trigger different modes of cell death, such as apoptosis, apoptosis-like and necrosis-like cell death. 1, 3 Therefore, it is currently admitted that LMP is a downstream event of cell death, but can also act as its initiator in certain circumstances. 1 As mentioned earlier, LMP can be elicited by various stress signals, including lysosomotropic agents.
As the impact of LMP in the death of chronic myelogenous leukemia (CML) cells has not been evaluated, we investigated the mechanism of action of Leu-Leu-OMe, a lysosomotropic agent, in imatinib-sensitive (IM-S) or -resistant (IM-R) K562 cell lines and in CD34 þ primary cells from CML patients. We have shown earlier that imatinib, the first-line treatment for CML patients, triggers LMP in both CML cell lines and in CD34 þ progenitor cells from CML patients, noticeably through CTSB-mediated degradation of p210-BCR-ABL. 4 In contrast to imatinib, which, besides inducing LMP, also elicits mitochondria-dependent apoptosis, Leu-Leu-OMe seems to target lysosomes directly. 1, 2 To assess LMP, K562 cells were first incubated with LysoTracker Green for 1 h at 37 1C before the addition of increasing concentrations of Leu-Leu-OMe for 12 or 24 h.
Leu-Leu-OMe triggered a time-and concentration-dependent increase in LMP (Figure 1a ), which correlated with CTSB redistribution from a lysosomal to a cytoplasmic compartment in IM-S and IM-R cells as well (Figure 1b) . Leu-Leu-OMe induced also caspase 3 activation in IM-S and IM-R cell lines, whereas, /ml) were incubated for either 12 or 24 h with increasing concentrations of Leu-Leu-OMe. After incubation with 75 nM LysoTracker-GREEN for 1 h, cells were analyzed for lysosomal leakage by flow cytometry. (b) IM-S and IM-R K562 cells were incubated for 24 h with Leu-Leu-OMe (0.5 and 1 mg/ml) and CTSB activity was determined in both cytoplasmic and microsomal fractions. (c) IM-S and IM-R K562 cells were incubated for 24 h with increasing concentrations of Leu-Leu-OMe or for 48 h with 1 mM imatinib in the presence or absence of 2.5 mM of the specific CTSB inhibitor CA-074Me. Caspase 3 activity was assessed in quadruplicates using z-DEVD-AMC as substrate. (d) IM-R K562 cells were incubated for 24 h with Leu-Leu-OMe (0.5 and 1 mg/ml) in the presence or absence of CA-074Me (2.5 mM). BCR-ABL and ABL protein levels were visualized by western blot. HSP60 was used as a loading control. (e) K562 IM-S cells growing in semi-solid methylcellulose medium (0.5 Â 10 3 cells/ml) were incubated in the presence of 1 mg/ml Leu-Leu-OMe, 2.5 mM CA-074Me or the combination of both effectors. Colonies were detected after 10 days of culture by adding 1 mg/ml of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reagent and were scored by Image J quantification software. Results are expressed as the percentage of colony forming cells after drug treatment in comparison to the untreated control cells. Results are the mean±s.d. of three different determinations. Error bars ¼ 95% confidence intervals.
Letters to the Editor as expected, imatinib triggered caspase 3 activation only in IM-S cells (Figure 1c) . Activation of caspase 3 by Leu-Leu-OMe was consecutive to CTSB activation, as it was prevented by CA-074Me, a specific CTSB inhibitor, which did not target caspases directly. 4 To investigate further the mechanisms governing the antileukemic action of Leu-Leu-OMe, we analyzed its effect on p210-BCR-ABL degradation, as we reported earlier that imatinib can trigger cleavage of this chimeric protein both in vitro and in vivo. 4 Interestingly, Leu-Leu-OMe also promoted Inhibition of CTSB protects CD34 þ CML primary cells from Leu-Leu-OMe-mediated cell death. CD34 þ primary cells were purified on magnetic beads coated with anti-CD34 monoclonal antibody. For each patient the purity of cells estimated by FACS was found to be at least 90% as described earlier. 4 (a) CD34 þ cells (10 3 cells/ml) from patients with CML were pre-incubated for 1 h with CA-074Me (2.5 mM) and treated for the next 48 h with Leu-Leu-OMe (1 mg/ml). Cell metabolism was assessed using the XTT assay. Results represent the mean±s.d. of four different determinations. (b) CD34 þ cells (10 3 cells/ml) from patients with CML were incubated for 14 days in semi-solid methylcellulose medium with either Leu-Leu-OMe (1 mg/ml) or CA-074Me (2.5 mM). Colonies were detected by adding 1 mg/ml of MTT reagent and were scored by using Image J quantification software. Results are expressed as the percentage of colony-forming cells after drug treatment versus untreated cells. Results represent the mean ± s.d. of three different determinations.
p210-BCR-ABL cleavage in its characteristic 55-kDa fragment in IM-R cells (Figure 1d ), an effect abolished by CA-074Me. In addition, CA-074Me inhibited drastically Leu-Leu-OMemediated loss of clonogenic potential in K562 cells, strongly suggesting that CTSB relocalization and activation are responsible for Leu-Leu-OMe-induced cell death (Figure 1e) . Thus, as a whole, our findings show that Leu-Leu-OMe eradicates K562 cells through LMP-mediated release of CTSB, which correlates with cleavage of p210-BCR-ABL.
As Leu-Leu-OMe concomitantly activated caspase 3 and CTSB in CML cells, we next investigated a possible interplay between these two pathways in eliminating CML cells. To this end, we first used a stable K562 cell line in which caspase 3 expression and activity can be knocked down by a specific short hairpin RNA. 5 Incubation of these cells with doxycyclin abrogated caspase 3 activation in response to Leu-Leu-OMe (Figure 2a) . Inhibition of caspase 3 correlated with a reduction of CTSB activation by Leu-Leu-OMe (Figure 2b) . In a second set of experiments, we knocked down CTSB with two specific small interfering RNAs (Figure 2c) . Interestingly, inhibition of CTSB also inhibited Leu-Leu-OMe-mediated caspase 3 activation (Figure 2d ). Therefore, CTSB and caspase 3 cooperate to mediate the anti-leukemic effect of Leu-Leu-OMe.
Accordingly, annexin V/propidium iodide staining of K562 cells revealed that two-thirds of Leu-Leu-OMe-induced cell death accounted for a CTSB-dependent mechanism, whereas the remaining was mediated by a caspase-dependent process (Supplementary Table 1 ). This CTSB-independent effect of Leu-Leu-OMe might reflect either caspase-dependent cell death or, alternatively, necrotic cell death. 6 Indeed, Leu-Leu-OMe has been shown to trigger apoptosis, while accumulation of free leucine generated from Leu-Leu-OMe causes disruption of lysosomes and subsequent cell necrosis. Nevertheless, a significant proportion of Leu-Leu-OMe's effect on CML cells seems to be primarily induced through CTSB activation.
Finally, it was of importance to investigate whether Leu-Leu-OMe could trigger LMP in CD34 þ progenitor cells from CML patients. Thus, we isolated CD34 þ cells from four different CML patients and analyzed cell viability and clonogenicity in the presence of this compound. Leu-Leu-OMe induced a drastic loss of viability and clonogenic potential of CD34 þ CML progenitors (Figures 3a and b) . Both responses were mitigated by CA-074Me, demonstrating that CTSB had also an important role in the anti-leukemic effect of Leu-LeuOMe on CML progenitors (Figures 3a and b) .
In conclusion, our findings show that Leu-LeuOMe triggers elimination of IM-S and IM-R CML cells through the release of CTSB into the cytoplasm and correlates with the cleavage of p210-BCR-ABL. Induction of lysosomal cell death has been proposed as a possible alternative to eradicate tumor cells. 1, 2, 7 Recently, Ivanov et al. 8 reported that Tosilumomab, a type II anti-CD20 monoclonal antibody, triggers B-cell lymphoma cell death by engaging the lysosomal compartment and activation of CTSB. Therefore, identifying cytotoxic compounds capable of activating the lysosomal cell death pathway may be an important challenge for future research and clinical applications in CML and more generally in leukemia.
